Welcome to our dedicated page for Innate Pharma S.A. ADS news (Ticker: IPHA), a resource for investors and traders seeking the latest updates and insights on Innate Pharma S.A. ADS stock.
Innate Pharma S.A. (Symbol: IPHA) is a clinical-stage biotechnology company at the forefront of cancer treatment innovation. Specializing in immuno-oncology, Innate Pharma develops first-in-class therapeutic antibodies designed to harness the innate immune system. This pioneering approach helps the body's natural defenses recognize and combat cancer cells more effectively.
The company's diverse pipeline includes four clinical-stage antibodies along with several preclinical candidates. Key products under development include lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401, and IPH6501. These therapies aim to address a wide range of cancer types, particularly those with high unmet medical needs.
Innate Pharma has made significant strides in the discovery and development of checkpoint inhibitors, leveraging its deep understanding of natural killer cell biology. This expertise has led to strategic partnerships with renowned biopharmaceutical companies such as AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S, and Sanofi.
The company’s revenue streams primarily come from research collaborations, licensing agreements, and milestone payments from its pharmaceutical partners. Innate Pharma's proprietary platform, ANKET (Antibody-based NK cell Engager Therapeutics), forms the backbone of its innovative therapeutic strategies.
With a commitment to advancing cancer treatment, Innate Pharma continues to make significant progress in clinical trials and research, aiming to bring transformative therapies to patients worldwide.
Innate Pharma has appointed Jonathan Dickinson as its new Chief Executive Officer and Chairman of the Executive Board, effective November 1, 2024. Dickinson, who most recently served as Executive Vice President and General Manager, Europe at Incyte, brings extensive experience from leadership roles in biotech and big pharma. He succeeds Hervé Brailly, co-founder and interim CEO, who will stay on in an advisory role to ensure a smooth transition.
Dickinson's career includes senior positions at ARIAD Pharmaceuticals, Bristol-Myers Squibb, and a 13-year tenure at Hoffmann-La Roche. He holds a Bachelor of Science in Genetics and an MBA from the University of Nottingham. The appointment aims to drive the advancement of Innate Pharma's immuno-oncology pipeline and position the company for future growth.
Innate Pharma is set to co-host a scientific symposium titled 'Next Generation Immunotherapy Discoveries' with the Icahn School of Medicine at Mount Sinai on October 3, 2024. The event, part of Innate Pharma's 25th anniversary celebration, will be held in a hybrid format in New York City and online from 10:00 a.m. to 5:30 p.m. EDT.
The symposium will showcase the latest advances in immunotherapy, featuring presentations from key opinion leaders in the field. Participants will have the opportunity to engage with speakers during Q&A sessions. Prior to the symposium, Innate Pharma will host an Investor and Analyst Meeting from 8:30 a.m. to 9:30 a.m. EDT to provide an overview of the company's therapeutic innovations.
The event will include speakers from prestigious institutions such as Memorial Sloan Kettering Cancer Center, Harvard Medical School, and UCLA Jonsson Comprehensive Cancer Center, among others.
Innate Pharma announced FDA clearance of its IND application for IPH4502, a novel topoisomerase I inhibitor antibody drug conjugate (ADC) targeting Nectin-4 in solid tumors. The company plans to initiate a Phase 1 clinical study in the coming months. The study will be an open-label, multi-center trial assessing the safety, tolerability, and preliminary efficacy of IPH4502 as a single agent in advanced solid tumors known to express Nectin-4, including urothelial carcinoma, non-small cell lung, breast, ovarian, gastric and colorectal cancers.
The study will include a Part 1 Dose Escalation and a Part 2 Dose Optimization. This marks Innate's first ADC program to enter clinical trials, representing a significant milestone for the company.
Innate Pharma reported its H1 2024 business update and financial results. Key highlights include:
- Positive Phase 2 results for lacutamab in mycosis fungoides presented at ASCO 2024
- NK-Cell engager SAR443579/IPH6101 advanced to Phase 2 and initiated front-line AML Phase 1/2 combination study
- IPH45 ADC progressing towards Phase 1 in H2 2024
- Cash position of €102.1 million as of June 30, 2024
- Revenue decreased to €12.3 million in H1 2024 from €40.2 million in H1 2023
- Operating expenses decreased slightly to €38.7 million in H1 2024 from €40.6 million in H1 2023
- R&D expenses decreased to €29.1 million in H1 2024 from €31.5 million in H1 2023
The company continues to advance its pipeline and maintains a cash runway until end of 2025.
Innate Pharma SA announced interim results from AstraZeneca's NeoCOAST-2 Phase 2 study presented at the 2024 World Conference on Lung Cancer. The study evaluates neoadjuvant durvalumab alone or combined with novel agents and chemotherapy in resectable, early-stage non-small cell lung cancer (NSCLC). Preliminary data from Arm 2 showed that monalizumab added to durvalumab plus platinum-based chemotherapy induced a pathological complete response rate of 26.7% and a major pathological response rate of 53.3%, numerically higher than the approved regimen. The treatment demonstrated a manageable safety profile with no impact on surgical rate. Innate Pharma's Chief Medical Officer expressed excitement about the potential of extending durvalumab's clinical benefit with monalizumab in NSCLC patients.
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) has announced a conference call and webcast scheduled for Thursday, September 12, 2024, at 2 p.m. CEST / 8 a.m. EDT. The event will provide an update on the company's business progress during the first half of 2024. Key participants will include CEO Hervé Brailly, CMO Sonia Quaratino, COO Yannis Morel, CFO Frédéric Lombard, and EVP and President of US Operations Arvind Sood.
Investors and interested parties can join the live webcast or participate via telephone. A replay of the webcast will be available on the company's website for 90 days following the event. This announcement suggests that Innate Pharma is preparing to share important financial results and business updates with its stakeholders.
Innate Pharma (Euronext Paris: IPH; Nasdaq: IPHA) has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 10, 2024, in New York, United States. Arvind Sood, EVP and President of US Operations, will represent the company at this investor conference. This participation provides Innate Pharma with an opportunity to engage with investors and showcase its business developments and potential investment prospects.
Innate Pharma (Euronext Paris: IPH; Nasdaq: IPHA) has announced its participation in the upcoming BTIG Virtual Biotechnology Conference, scheduled for August 5-6, 2024. The company will be represented by key executives, including Yannis Morel, EVP and Chief Operating Officer, and Arvind Sood, EVP and President of US Operations.
This virtual conference provides an opportunity for Innate Pharma to engage with investors and showcase its latest developments in the biotechnology sector. The company's presence at such events is important for maintaining investor relations and potentially attracting new investment opportunities.
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) has released its total number of shares outstanding and voting rights as of July 10, 2024. The company's share structure includes 80,969,357 ordinary shares, 6,494 Preferred Shares 2016, and 7,581 Preferred Shares 2017. The total number of theoretical voting rights stands at 81,724,597, while the total number of exercisable voting rights is 81,706,022. This disclosure is in compliance with French regulatory requirements and aims to keep the market adequately informed about the company's share structure and voting rights distribution.
Innate Pharma SA reported its total number of shares and voting rights as of June 10, 2024.
The company has 80,967,407 ordinary shares, 6,509 Preferred Shares 2016, and 7,581 Preferred Shares 2017.
The total number of theoretical voting rights stands at 81,724,597, while the number of exercisable voting rights is 81,706,022.
This information is disclosed to comply with regulations by the AMF, ensuring market transparency.
FAQ
What is the current stock price of Innate Pharma S.A. ADS (IPHA)?
What is the market cap of Innate Pharma S.A. ADS (IPHA)?
What does Innate Pharma S.A. specialize in?
What are some of Innate Pharma's key products?
How does Innate Pharma generate revenue?
Who are some of Innate Pharma's notable partners?
What is ANKET?
What is the focus of Innate Pharma’s current projects?
What stage is Innate Pharma in?
What makes Innate Pharma's approach unique?
What is immuno-oncology?
How does Innate Pharma contribute to cancer research?
